Adjunct MMA embolization versus conventional burr hole for CSDH

Phase 2

Completed

• Conditions: Chronic subdural hematoma; chronic subdural hematoma; middle meningeal artery embolization; MMA embolization; CSDH; endovascular CSDH treatment

• Registration Number: TCTR20221014001
• Lead Sponsor: Faculty of medicine, Thammasat university

Brief Summary

This study suggests that adjunctive MMAE is a promising addition to surgical drainage for the treatment of CSDH. MMAE shows acceptable safety and is associated with significant hematoma reduction and a potential decrease in recurrent cases compared to SDA. These findings warrant further exploration through a randomized trial to validate the efficacy of MMAE in CSDH management.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-14
• Study Completion: 2023-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

All patients with age >= 18 years old who diagnosed with chronic subdural hematoma

Exclusion Criteria

1.Had previous brain surgery within 3 months
2.GCS < 5 or NIHSS < 5
3.CSDH from brain tumor, vascular diseases
4.Pregnancy
5.chronic kidney disease or ongoing dialysis
6.infratentorium intracerebral hemorrhage
7.bed ridden or vegetative state
8.Patients with dangerous ECA anastomoses

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Subdural hematoma thickness Post-op, 14, 30, 90, 180 days Subdural hematoma from CT brain,Subdural hematoma volume Post-op, 14, 30, 90, 180 days 3D-computer assisted software

Secondary Outcome Measures

Name	Time	Method
recurrence 6 months Subdural hematoma from CT brain,complications 6 months any complication related to procedures